



Correction to: Hepatitis B Surface Antigen Loss with Tenofovir Disoproxil Fumarate Plus Peginterferon Alfa-2a: Week 120 Analysis

Sang Hoon Ahn¹ · Patrick Marcellin² · Xiaoli Ma³ · Florin A. Caruntu⁴ · Won Young Tak⁵ · Magdy Elkhatab⁶ · Wan-Long Chuang⁷ · Fehmi Tabak⁸ · Rajiv Mehta⁹ · Jörg Petersen¹⁰ · William Guyer¹¹ · Belinda Jump¹¹ · Alain Chan¹¹ · Mani Subramanian¹¹ · Gerald Crans¹¹ · Scott Fung¹² · Maria Buti¹³ · Giovanni B. Gaeta¹⁴ · Aric J. Hui^{15,16} · George Papatheodoridis¹⁷ · Robert Flisiak¹⁸ · Henry L. Y. Chan¹⁹

Published online: 15 October 2018
© The Author(s) 2018

Correction to: Digestive Diseases and Sciences <https://doi.org/10.1007/s10620-018-5251-9>

The original version of this article unfortunately contained affiliation and textual errors. This has been corrected with this erratum.

Affiliation of eleventh author was incorrectly assigned. Dr. William Guyer is affiliated with Gilead Sciences Inc, Foster City, CA, USA.

In Results section, Safety Profile subsection, the sentence, ‘Rates of serious adverse events were 11%, 10%, 7%, and

10% in groups A, B, C, and D, respectively, and 6%, 3%, and 5% in groups A, B, and D, respectively, among those patients who were treated with TDF’ should read as below:

Rates of serious adverse events were 11%, 10%, 7%, and 10% in groups A, B, C, and D, respectively, and 6%, 3%, and 5% in groups A, B, and D, respectively, among those patients who were retreated with TDF.

In Table 2, header ‘Mean HBV DNA change from baseline, log₁₀ IU/mL (SD)’ row 3 is missing ‘B’ in genotype. Revised version of the Table 2 is given below.

The original article can be found online at <https://doi.org/10.1007/s10620-018-5251-9>.

✉ Patrick Marcellin
patrick.marcellin@bjn.aphp.fr

✉ Henry L. Y. Chan
hlychan@cuhk.edu.hk

Sang Hoon Ahn
ahnsh@yuhs.ac

Xiaoli Ma
tangmali@yahoo.com

Florin A. Caruntu
drcaruntu@mateibals.ro

Won Young Tak
wytak@knu.ac.kr

Magdy Elkhatab
melkashabmd@yahoo.ca

Wan-Long Chuang
waloch@kmu.edu.tw

Fehmi Tabak
fehmitabak@hotmail.com

Rajiv Mehta
rmgastro@yahoo.com

Jörg Petersen
petersen@ifi-medizin.de

William Guyer
william.guyer@gilead.com

Belinda Jump
belinda.jump@gilead.com

Alain Chan
alain.chan@gilead.com

Mani Subramanian
mani.subramanian@gilead.com

Gerald Crans
gerald.crans@gilead.com

Scott Fung
scott.fung@uhn.on.ca

Maria Buti
mbuti@vhebron.net

Giovanni B. Gaeta
giovannibattista@unicampania.it

Aric J. Hui
arichui@yahoo.com

Table 2 Efficacy results at week 120 by baseline HBeAg status and genotype

Response	Group A (n = 186) TDF + PEG-IFN for 48 weeks	Group B (n = 184) TDF + PEG-IFN for 16 weeks, TDF for 32 weeks	Group C (n = 185) TDF for 120 weeks	Group D (n = 185) PEG-IFN for 48 weeks
HBsAg loss, Kaplan–Meier estimate (%)				
Overall	10.36	3.49	0	3.51
HBeAg positive	9.73	5.15	0	5.23
HBeAg negative	10.99	1.32	0	1.28
HBsAg seroconversion, Kaplan–Meier estimate (%)				
Overall	10.08	0.56	0	2.87
HBeAg positive	10.41	0.97	0	4.10
HBeAg negative	9.65	0	0	1.28
Mean HBsAg change from baseline, log ₁₀ IU/mL (SD)				
Overall	−2.4 (2.4)	−0.8 (1.5)	−0.4 (0.7)	−1.1 (1.6)
Genotype A	−4.2 (2.3)	–	−0.7 (1.2)	0.0 (0.6)
Genotype B	−2.2 (2.1)	−1.0 (1.0)	−0.7 (0.6)	−1.2 (1.2)
Genotype C	−1.5 (2.2)	−0.4 (1.5)	−0.4 (0.7)	−1.1 (1.7)
Genotype D	−2.0 (2.3)	−1.6 (2.6)	−0.2 (0.4)	−1.5 (2.9)
HBeAg positive	−2.2 (2.6)	−1.2 (1.9)	−0.7 (0.7)	−1.3 (2.1)
HBeAg negative	−2.5 (2.1)	−0.4 (0.9)	−0.1 (0.4)	−1.0 (1.1)
Mean HBV DNA change from baseline, log ₁₀ IU/mL (SD)				
Overall	−4.2 (2.1)	−4.3 (2.0)	−5.7 (1.6)	−3.5 (2.0)
Genotype A	−4.0 (1.9)	–	−5.1 (2.1)	−1.9 (2.0)
Genotype B	−4.7 (2.0)	−4.2 (2.5)	−5.8 (1.4)	−3.3 (1.8)
Genotype C	−4.2 (2.9)	−4.4 (1.5)	−5.9 (1.6)	−3.4 (2.3)
Genotype D	−4.0 (1.8)	−4.1 (3.0)	−5.3 (1.7)	−5.1 (1.9)
HBeAg positive	−5.5 (1.6)	−5.3 (1.5)	−6.6 (1.2)	−4.9 (1.6)
HBeAg negative	−2.9 (1.7)	−3.4 (1.9)	−4.5 (1.3)	−2.5 (1.8)

George Papatheodoridis
gepapath@med.uoa.gr

Robert Flisiak
robert.flisiak@umwb.edu.pl

¹ Department of Internal Medicine, Yonsei University College of Medicine, Brain Korea 21 Plus Project for Medical Science, Seoul, Republic of Korea

² Hôpital Beaujon, University Paris-Diderot, Clichy, France

³ Drexel University College of Medicine, Philadelphia, PA, USA

⁴ National Institute for Infectious Diseases “Matei Bals”, Bucharest, Romania

⁵ Kyungpook National University Hospital, Daegu, South Korea

⁶ Toronto Liver Centre, Toronto, Canada

⁷ Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan

⁸ Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey

⁹ Liver Clinic, Surat, India

¹⁰ IFI Institute for Interdisciplinary Medicine, Asklepios Klinik St. George, University of Hamburg, Hamburg, Germany

¹¹ Gilead Sciences Inc, Foster City, CA, USA

¹² Toronto General Hospital, Toronto, Canada

¹³ Hepatology Unit, Hospital Universitari Vall d’Hebron and CIBEREHD del Instituto Carlos III, Barcelona, Spain

¹⁴ Infectious Diseases and Viral Hepatitis Unit, University of Campania “Luigi Vanvitelli”, Naples, Italy

¹⁵ The Chinese University of Hong Kong, Hong Kong, China

¹⁶ Alice Ho Miu Ling Nethersole Hospital, Hong Kong, China

¹⁷ Medical School of National and Kapodistrian University of Athens, General Hospital of Athens “Laiko”, Athens, Greece

¹⁸ Department of Infectious Diseases and Hepatology, Medical University of Bialystok, Bialystok, Poland

¹⁹ Department of Medicine and Therapeutics and Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong, China